Table 1.

Clinical and radiographic outcomes of superior capsular reconstruction.

Year	Reference	Patients, n	Implant	Average follow-up (months)	Pre- to post-op clinical outcomes		Intact graft rate	Failure rate
					ASES	VAS
2013	Mihata et al.(64)	23	Fascia lata autograft	34.1	23.5 → 92.9		83.3%	4.3%
2017	Denard et al.(65)	59	Dermal allograft†	17.7	43.6 → 77.5	5.8 → 1.7	45%	18.6%
2017	Hirahara et al.(66)	8	Dermal allograft†	32.4	43.5 → 86.5	6.3 → 0.4		21.5%
2018	Lee & Min (67)	32	Fascia lata autograft or allograft‡	24.8	50.3 → 84	5.8 → 1.34	63.9%	36.1%
2018	Lim et al. (68)	31	Fascia lata allograft	12.8	54.4 → 73.7	6 → 2.5	71%	29%
2018	Mihata et al.(69)
	No pseudoparalysis	45	Fascia lata allograft	60	43.6 → 96.5		98%	2%
	Moderate pseudoparalysis	28			29.2 → 92.2		96%	4%
	Severe pseudoparalysis	15			20.3 → 91.8		87%	13%
2018	Pennington et al. (70)	86	Dermal allograft†	Minimum 12	52.2 → 81.6	4.0 → 1.5		4.5%
2019	Burkhart & Hartzler (71)	10	Dermal allograft†	12.9	52 → 89	4.6 → 0.5
2019	Burkhart et al. (40)	41	Dermal allograft†	34	52 → 90	4.6 → 0.7	85%	5%
2020	Lacheta et al. (39)	22	Dermal allograft†	25.2	54.0 → 83.9	4 → 0	Tuberosity: 100% Midsubstance: 76% Glenoid: 81%	3.7%
2021	Okamura et al. (72)		Teflon§	42				13%
	1 teflon layer	15			42.4 → 63.2
	3 teflon layers	20			40.3 → 71.4			0%

^†Arthroflex, Arthrex, Naples, FL, USA; ^‡MegaDerm® allodermis, L&C BIO, Seoul, Korea; ^§Bard PTFE Felt, C.R. Bard, Inc., Murray Hill, NJ, USA.

ASES, American Shoulder and Elbow Surgeons score; VAS, visual analog score.